Ole Norling Mathiassen

Ole Norling Mathiassen

Auto-generated profile, based on publicly available information

Ole Norling Mathiassen

Department of Pharmacology, University of Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2007 in Journal Of Hypertension
Verified
Journal Article
Closed access
OMOle N Mathiassen
Ole N Mathiassen
NBNiels Henrik Buus
Niels Henrik Buus
ISInger Sihm
Inger Sihm
NTNiels K Thybo
Niels K Thybo
BMBirgitte Mørn
Birgitte Mørn
KCKent L Christensen
Kent L Christensen
Structural abnormality of resistance arteries is a characteristic pathophysiological phenomenon in essential hypertension and can be assessed in vitro as an increase in the media: lumen ratio (M: L) of isolated small arteries. We have investigated whether M: L is a risk predictor in uncomplicated essential hypertensive patients. Recently, high M: L was demonstrated as a prognostic marker in patients at high cardiovascular risk, including normotensive type 2 diabetic patients. Since diabetes is associated with pressure-independent changes in M: L, the relevance of this finding to essential hypertension has been uncertain. We conducted a follow-up survey of 159 essential hypertensive patients, who had previously been submitted to a M: L evaluation while participating in a clinical trial. They composed a homogeneous moderate-risk group, with no concomitant diseases, and represented 1661 years of follow-up. Thirty patients suffered a documented predefined cardiovascular event during follow-up. Increased relative risk (RR) was associated with M: L >or= 0.083 (mean level of the hypertensive cohort), RR = 2.34 [95% confidence interval (CI) 1.11-4.95], and with M: L >or= 0.098 (mean level of a normotensive control group + 2SD), RR = 2.49 (95% CI 1.21-5.11). Both results remained significant (RR = 2.19, 95% CI 1.04-4.64, and RR = 2.20, 95% CI 1.06-4.56, respectively) when adjusted for Heart Score level (10-year mortality risk-estimate, integrating age, gender, systolic blood pressure, cholesterol and smoking). Abnormal resistance artery structure independently predicts cardiovascular events in essential hypertensive patients at moderate risk.

1 August 2016 in Journal Of Hypertension
Verified
Journal Article
Open access
OMOle N. Mathiassen
Ole N. Mathiassen
HVHenrik Vase
Henrik Vase
JBJesper Nørgaard Bech
Jesper Nørgaard Bech
KCKent L. Christensen
Kent L. Christensen
NBNiels Henrik Buus
Niels Henrik Buus
AKAnne Kaltoft
Anne Kaltoft
Renal denervation (RDN), treating resistant hypertension, has, in open trial design, been shown to lower blood pressure (BP) dramatically, but this was primarily with respect to office BP. We conducted a SHAM-controlled, double-blind, randomized, single-center trial to establish efficacy data based on 24-h ambulatory BP measurements (ABPM). Inclusion criteria were daytime systolic ABPM at least 145 mmHg following 1 month of stable medication and 2 weeks of compliance registration. All RDN procedures were carried out by an experienced operator using the unipolar Medtronic Flex catheter (Medtronic, Santa Rosa, California, USA). We randomized 69 patients with treatment-resistant hypertension to RDN (n = 36) or SHAM (n = 33). Groups were well balanced at baseline. Mean baseline daytime systolic ABPM was 159 ± 12 mmHg (RDN) and 159 ± 14 mmHg (SHAM). Groups had similar reductions in daytime systolic ABPM compared with baseline at 3 months [-6.2 ± 18.8 mmHg (RDN) vs. -6.0 ± 13.5 mmHg (SHAM)] and at 6 months [-6.1 ± 18.9 mmHg (RDN) vs. -4.3 ± 15.1 mmHg (SHAM)]. Mean usage of antihypertensive medication (daily defined doses) at 3 months was equal [6.8 ± 2.7 (RDN) vs. 7.0 ± 2.5 (SHAM)].RDN performed at a single center and by a high-volume operator reduced ABPM to the same level as SHAM treatment and thus confirms the result of the HTN3 trial. Further, clinical use of RDN for treatment of resistant hypertension should await positive results from double-blinded, SHAM-controlled trials with multipolar ablation catheters or novel denervation techniques.

1 May 2007 in Journal Of Hypertension
Verified
Journal Article
Closed access
OMOle N Mathiassen
Ole N Mathiassen
NBNiels Henrik Buus
Niels Henrik Buus
MLMogens L Larsen
Mogens L Larsen
MMMichael J Mulvany
Michael J Mulvany
KCKent L Christensen
Kent L Christensen
Correction of the abnormal structure of resistance arteries in essential hypertension may be an important treatment goal in addition to blood pressure (BP) reduction. We investigated how this may be achieved in a prospective clinical study. Plethysmography was used to measure forearm resting vascular resistance (Rrest) and minimum vascular resistance (Rmin) as a measure of vascular structure. Two different groups of patients with essential hypertension were examined at baseline and after 6 months of antihypertensive treatment. In group A, 21 patients with never-treated essential hypertension were treated by their general practitioners using a variety of drugs to allow an assessment of the drug-independent effects. In group B, 28 beta-blocker-treated patients were shifted to angiotensin II receptor blocker treatment (eprosartan) to allow vasodilatation with no change in BP. In group A, mean ambulatory blood pressure (ABP) fell from 119 +/- 2 (SE) to 103 +/- 2 mmHg (P < 0.01), whereas mean ABP was unchanged in group B (100 +/- 1 to 99 +/- 1 mmHg, P = NS). Both groups showed similar reductions in Rrest (-33.4 and -28.5%, respectively) and in Rmin (-15.4 and -15.6%, respectively). There was a strong correlation between changes in Rrest and Rmin within both groups (r = 0.57, P < 0.01 and r = 0.68, P < 0.0001, respectively), whereas the change in BP in group A was not correlated to the change in Rmin (r = -0.03). The correction of forearm resistance artery structure during antihypertensive treatment depends on the vasodilatation achieved rather than BP reduction.

9 August 2006 in Acta Physiologica
Verified
Journal Article
Closed access
PDF file
OMO. N. Mathiassen
O. N. Mathiassen
NBNiels Henrik Buus
Niels Henrik Buus
HOH. W. Olsen
H. W. Olsen
MLM. L. Larsen
M. L. Larsen
MMM. J. Mulvany
M. J. Mulvany
KCK. L. Christensen
K. L. Christensen

24 May 2017 in American Journal of Case Reports
Verified
Journal Article
Open access
PDF file
OMOle Norling Mathiassen
Ole Norling Mathiassen
EGErik Lerkevang Grove
Erik Lerkevang Grove
NHNicolaj Christoffer Hansson
Nicolaj Christoffer Hansson
BNBjarne Linde Norgaard
Bjarne Linde Norgaard
BACKGROUND:Although transcatheter aortic valve replacement (TAVR) has become a worldwide and generally accepted treatment of patients with aortic stenosis at high surgical risk, there is a rising concern and debate about the occurrence of transcathet...

2 June 2014
Verified
Journal Article
Closed access
OMOle Norling Mathiassen
Ole Norling Mathiassen
HIHans Ibsen
Hans Ibsen